文献速递胰腺与胆道疾病消化内镜

乳酸林格氏液联合直肠吲哚美辛预防ERCP后胰腺炎与再入院:前瞻性随机双盲安慰剂对照试验

Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial.
PubMed 文献 · Gastrointest Endosc · 2016-11-02

这项前瞻性随机双盲安慰剂对照试验纳入192例ERCP后胰腺炎高危患者,随机分为生理盐水+安慰剂、生理盐水+吲哚美辛、乳酸林格氏液+安慰剂、乳酸林格氏液+吲哚美辛四组。乳酸林格氏液+吲哚美辛组胰腺炎发生率为6%,低于生理盐水+安慰剂组的21%(P = .04),再入院率亦较低(2% vs 13%,P = .03)。

要点

  • 乳酸林格氏液联合直肠吲哚美辛组胰腺炎发生率为6%,低于生理盐水+安慰剂组的21%(P = .04)。
  • 乳酸林格氏液联合直肠吲哚美辛组再入院率为2%,低于生理盐水+安慰剂组的13%(P = .03)。
  • 其他研究组间未发现差异。

核心结论

  • 在高危患者中,乳酸林格氏液联合直肠吲哚美辛与生理盐水+安慰剂相比降低了ERCP后胰腺炎发生率和再入院率。

研究设计与样本

  • 前瞻性随机双盲安慰剂对照试验,纳入192例ERCP后胰腺炎高危患者,每组48例,完成24小时及ERCP后30天随访。

主要发现

  • 乳酸林格氏液+吲哚美辛组胰腺炎发生3例(6%),生理盐水+安慰剂组10例(21%)(P = .04)。
  • 乳酸林格氏液+吲哚美辛组再入院1例(2%),生理盐水+安慰剂组6例(13%)(P = .03)。
  • 其他研究组间未发现差异。
  • 重度胰腺炎1例(生理盐水+吲哚美辛组),假性囊肿1例(乳酸林格氏液+吲哚美辛组)。

临床怎么用

  • 作者结论认为,对于ERCP后胰腺炎高危患者,乳酸林格氏液联合直肠吲哚美辛较生理盐水+安慰剂可降低胰腺炎发生率和再入院率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Prospective data have shown the benefit of rectal indomethacin (IND) for preventing post-ERCP pancreatitis (PEP). A recent pilot study demonstrated a lower incidence of PEP after an 8-hour lactated Ringer's solution (LR) infusion. The aim of this study was to evaluate the efficacy of IND with or without bolus LR in patients at high-risk for PEP. METHODS: In this randomized, double-blinded, placebo-controlled trial we assigned patients to standard normal saline solution (NS) + placebo, NS + IND, LR + placebo, or LR + IND. Each liter of fluid infusion was completed within 30 minutes. Patients were determined high-risk based established criterion and excluded if they had pancreatitis, contraindications to IND, or signs of volume overload. Our primary outcome was PEP, defined by standardized criterion. Our secondary outcomes were severe acute pancreatitis, localized adverse events, death, length of stay, and readmission. RESULTS: Our sample consisted of 192 patients (48 per group) who completed follow-up at 24 hours and at 30 days post-ERCP. All patients had at least 1 high-risk criterion for PEP, and 56% had >1. PEP occurred in 3 patients (6%) in the LR + IND versus 10 (21%) in the NS + placebo group (P = .04). Readmission rates were lower in the LR + IND group (1 [2%]) versus the NS + placebo group (6 [13%]; P = .03). No differences were found between the other study groups. There was 1 case of severe pancreatitis (NS + IND) and 1 case of pseudocyst (LR + IND). CONCLUSIONS: In patients at high risk for PEP, LR + IND reduced the incidence of PEP and readmission rates compared with NS + placebo. (Clinical trial registration number: NCT02641561.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Mok SRS, Ho HC, Shah P, et al. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial. Gastrointest Endosc. 2016. PMID: 27816497. doi:10.1016/j.gie.2016.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。